Search Results
Your search for ,WHo matches 20376 pages
Showing 14751 - 14800Many Americans Favor a Tax Increase to Support the 'Moonshot' Cancer Initiative
Vice President Joe Biden's “moonshot” initiative to defeat cancer earned support for a tax increase to fund cancer research among half of respondents (50%) in a new national public opinion survey commissioned by Research!America. Thirty-eight percent disagree and an additional 12% are...
Study Finds Need for Improved End-of-Life Care for Parents With Terminal Cancer
Care for mothers with terminal cancer could be improved to help resolve their psychological distress and to help surviving family members cope, a study by University of North Carolina at Chapel Hill researchers have found. Based on the study findings published by Park et al in the journal BMJ...
Increased Breast Cancer Risk Reported in Childhood Sarcoma and Leukemia Survivors With No History of Chest Radiotherapy
In an analysis of the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Henderson et al found that childhood survivors of sarcoma and leukemia with no history of chest radiotherapy were at an increased risk of breast cancer. Increased Risk The study included data from...
UK Study Finds No Association Between Self-Reported Unhappiness and Mortality Risk
As reported in The Lancet by Liu et al, a study in UK women that attempted to adjust for the effect of health and lifestyle factors found that self-reported unhappiness was not associated with an increased risk of mortality from cancer or other conditions. Study Details The study involved data...
Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial
Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive...
Julia H. Rowland, PhD, on The Psychosocial Challenges Cancer Survivors Face
Julia H. Rowland, PhD, of the National Cancer Institute, discusses the growing number of promising interventions to improve health and function for those living with and beyond a cancer diagnosis, as well as those who care for and about them.
Jennifer King, PhD: Scientific Perspectives From the Lung Cancer Alliance
Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.
William D. Travis, MD, on Pathology and Genetics of Lung Tumors: 2015 WHO Classification
William D. Travis, MD, of Memorial Sloan Kettering Cancer Center, gives an update on the WHO classification, which is crucial for optimal personalized treatment of lung cancer patients (Abstract PLEN02.01).
Barbara J. Gitlitz, MD: Genomics of Young Lung Cancer Study
Barbara J. Gitlitz, MD, of USC/Norris Cancer Center, discusses the first prospective study on the genomic drivers and demographics of lung cancer in patients under 40 who took part in the study remotely via the Internet (Abstract ORAL22.05).
Martine Frouws, MSc, PhD, on Postdiagnosis Aspirin and Improved Survival in All GI Cancers
Martine Frouws, MD, PhD Candidate, of Leiden University Medical Centre discusses her study, which showed a significant increase in overall survival among patients with GI cancers who took aspirin compared to those who did not (Abstract 2306).
Judith Vick, MD Candidate, and Rachelle E. Bernacki, MD, on A New Clinical Tool: The “Surprise Question”
Judith Vick, MD Candidate, of Johns Hopkins University School of Medicine, and Rachelle E. Bernacki, MD, of Dana-Farber Cancer Institute, discuss a tool that could help clinicians identify seriously ill patients who would benefit from conversations about their goals and values (Abstract 8).
ASCO Praises President’s Sharp Focus on Cancer
ASCO applauds President Obama for his bold vision to launch a national effort on cancer, which he described during his State of the Union address on January 12, 2016. We also join him in recognizing Vice President Biden’s leadership in calling for a “moonshot” that will reduce the cancer-related...
USPSTF Recommendation Confirms Value of Screening Mammography
The recently updated U.S. Preventive Services Task Force (USPSTF) recommendation once again confirmed the value of screening mammography, concluding that the benefit of mammography outweighs the harms of screening in all age groups from age 40 through age 74. It emphasizes that both women and...
Evolution
Ten years ago, ASCO created the Journal of Oncology Practice to address a gap in the literature; there were no peer-reviewed journals dedicated to the practical issues of delivering quality oncology care. The original research and editorials published in JOP focus on care delivery topics such as...
Nationally Regarded Cancer Advocate Ellen Stovall Dies
Passion is a much-needed virtue in one who seeks to change the world for the better. When you combine intelligence, stamina, iron-willed determination, the grace of an ambassador, and simple human likability with passion, you get that rare person who can turn words and ideas into reality. Such a...
Keeping Up With How Drugs Work
I love reading The ASCO Post, but I have a suggestion. For your reports on drug development, how about making it a policy to note the class or type of any new agent being discussed—ie, a brief description of the drug’s mechanism of action? For example, a recent issue included a nice article...
Expect Questions About Ovarian Cancer Screening
The authors of an ovarian cancer screening study published in The Lancet1 and many of the experts commenting on the study in the media agree that the results of multimodal screening are encouraging and could reduce mortality from ovarian cancer, but further follow-up is needed. Considering that the ...
Same Study, Different Interpretations
An article in The New York Times1 about an ovarian cancer screening study published in The Lancet2 is headlined, “Early Detection of Ovarian Cancer May Become Possible,” and leads with the promise of reduced mortality with multimodal screening for ovarian cancer. An article in MedPage Today3 about...
Could a Screening Test That Would Reduce Deaths From Ovarian Cancer Be on the Way?
"A solid triple but not a home run” is how Karen H. Lu, MD, characterized a study in The Lancet reporting a reduction in deaths from ovarian cancer with the use of multimodal ovarian cancer screening.1 Dr. Lu’s remark was one of several, mostly but not universally, favorable and optimistic comments ...
Rakesh Jain, PhD, and Mary-Claire King, PhD, Awarded the National Medal of Science
Rakesh Jain, PhD, the A. Werk Cook Professor of Radiation Oncology (Tumor Biology) at Harvard Medical School and Massachusetts General Hospital, and Mary-Claire King, PhD, Professor of Genome Sciences and Medicine (Medical Genetics) at the University of Washington, have been selected as recipients...
Pieces of Grief
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
American Psychosocial Oncology Society Endorses Psychosocial Standards of Care for Children With Cancer and Their Families
The American Psychosocial Oncology Society (APOS) has endorsed the “Psychosocial Standards of Care for Children With Cancer and Their Families,” which were published in a December 2015 special supplement of Pediatric Blood & Cancer. The scientific, evidence-based psychosocial standards define...
Ravi Salgia, MD, PhD, Joins City of Hope
Medical oncologist and researcher Ravi Salgia, MD, PhD, has joined City of Hope as Professor and Chair in the Department of Medical Oncology & Therapeutics Research. He will play a key leadership role in the expansion of clinical programs at City of Hope’s Duarte campus and in its clinics...
A Noted Breast Surgeon’s Book of Solid Advice
Bookmark Title: The New Generation Breast Cancer Book: How to Navigate Your Diagnosis and Treatment Options—and Remain Optimistic—in an Age of Information Overload Author: Elisa Port, MD Publisher: Ballantine Books Publication date: September 2015 Price: $20.00; paperback, 320 pages When a new...
Saving Children Orphaned by AIDS in South Africa
Bookmark Title: Empty Hands, A Memoir: One Woman’s Journey to Save Children Orphaned by AIDS in South Africa Author: Sister Abegail Ntleko Publisher: North Atlantic Books Publication date: September 1, 2015 Price: $12.95; paperback, 176 pages With the development of the multidrug highly active...
Stage Increase in Lung Cancer More Frequent After Open vs Closed Thoracic Surgery
An increase in the stage of non–small cell lung cancer (NSCLC) due to cancer-positive lymph node discovery was more common following open chest surgery for lung lobe removal of early-stage lung cancer compared to the closed-chest procedure known as video-assisted thoracic surgery (VATS). The...
Acupuncture for Cancer Symptom Clusters
Acupuncture has been practiced for thousands of years in Eastern Asian cultures as a component of traditional Chinese medicine.1 In the United States, acupuncture became known to the public as a complementary and alternative medicine technique in the 1970s, but it took many years before it was...
Ibrutinib in Relapsed Mantle Cell Lymphoma
Treatment of mantle cell lymphoma continues to evolve, both in the front-line and relapsed settings. Key advances include better use of established agents, such as the incorporation of high-dose cytarabine into initial induction regimens and application of rituximab (Rituxan)...
Phase III Trial Shows Improved Progression-Free Survival With Ibrutinib vs Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma
In aphase III trial reported in The Lancet and at the recent American Society of Hematology Annual Meeting and Exposition, Martin Dreyling, MD, of the European Mantle Cell Lymphoma Network, and colleagues found that ibrutinib (Imbruvica) was associated with improved progression-free survival vs...
New Society of Breast Imaging Website Seeks to End Confusion Surrounding Mammography Screening
Breast cancer is the second-leading cause of cancer deaths among women in the United States. In 2015, according to the National Cancer Institute, 231,840 women were to be diagnosed with the disease and 40,290 were to die from it. The death rate is highest among women who are not screened regularly...
Winning the Battle at the Front Lines: Lenalidomide Plus Rituximab— A Promising Initial Treatment for Mantle Cell Lymphoma
Mantle cell lymphoma is a pernicious, incurable disease. Front-line therapies for this disease are not currently standardized; however, novel therapies for relapsed or refractory mantle cell lymphoma can ideally be translated into beneficial treatments for newly diagnosed patients, as clearly...
Lenalidomide Plus Rituximab Highly Active in Initial Treatment of Mantle Cell Lymphoma
In a phase II trial reported in The New England Journal of Medicine by Jia Ruan, MD, PhD, and colleagues, first-line treatment with the immunomodulatory agent lenalidomide (Revlimid) and the anti-CD20 antibody rituximab (Rituxan) followed by maintenance lenalidomide and rituximab produced a high...
Terence S. Dermody, MD, Named Chair of Pediatrics at UPMC and Scientific Director of Children’s Hospital of Pittsburgh
Terence S. Dermody, MD, has been named the Chair of the Department of Pediatrics at the University of Pittsburgh School of Medicine and Physician-in-Chief and Scientific Director at Children’s Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC). Dr. Dermody will officially...
Community Oncology Alliance Elects New Officers and Board Members for 2016
The Community Oncology Alliance (COA), a nonprofit organization dedicated to advocating for community oncology practices and the patients they serve, announced the election of a new Board of Directors and Executive Committee officers. “2016 is primed to be an important year for community oncology....
The New Frontiers of Breast Cancer
A seismic shift is underway in screening and treatment approaches for breast cancer. These changes are being fueled by studies showing that mammography in younger women may do more harm than good and that advances in genomic testing and a better understanding of the biology of breast cancers may...
How Effective Communication Can Improve Patient Care—and Reduce Physician Burnout
Surveys conducted between 1950 and 1970 show that most physicians considered it inhumane to give patients with a poor cancer prognosis the bad news.1,2 Since then, it has been well established that open communication between physician and patient is an essential part of effective cancer care and...
The Evolving Treatment Landscape of ALK-Positive NSCLC
Since the initial discovery of ALK rearrangement in non–small cell lung cancer (NSCLC) in 2007,1 small molecule tyrosine kinase inhibitors of ALK have transformed the course of disease for those patients with ALK-rearranged (ie, ALK-positive) NSCLC. Crizotinib (Xalkori), a multitargeted tyrosine...
International Innovation Grant Supports Novel Breast Cancer Health Education Program in Mexico
The International Innovation Grant, funded by the Conquer Cancer Foundation (CCF) of ASCO, provides research funding in support of novel and innovative projects that can have a significant impact on cancer control in low- and middle-income countries. The grant is intended to support research that...
Conquer Cancer Foundation Hosts Inaugural Scientific and Career Development Retreat
In October 2015, the Conquer Cancer Foundation of ASCO (CCF) hosted its first Scientific and Career Development Retreat at ASCO Headquarters in Alexandria, Virginia, for past recipients of the Young Investigator Award (YIA) and Career Development Award (CDA). The YIA provides funding to promising...
Global and North American Phase II Studies Show Alectinib Is Highly Active in Crizotinib-Resistant/Refractory ALK-Rearranged NSCLC
In two phase II trials, reported in the Journal of Clinical Oncology and The Lancet Oncology, the ALK inhibitor alectinib (Alecensa), which is active against acquired crizotinib resistance mutations and exhibits high central nervous system (CNS) penetration, was associated with considerable...
Blood Test Can Predict High-Risk Cancers in Patients Treated With CAR-T
Dramatic advances have been made in using genetically engineered chimeric antigen receptor–modified T cells (CAR-T) with anti-CD19 specificity to treat highly refractory hematologic malignancies. The highest complete remission rates have been achieved in patients with relapsed or refractory acute...
Expert Point of View: Sagar Lonial, MD
Responding to the assertion that bortezomib (Velcade)/lenalidomide (Revlimid)/low-dose dexamethasone induction followed by continuous lenalidomide/dexamethasone is potentially a new standard of care in newly diagnosed multiple myeloma, Sagar Lonial, MD, Chief Medical Officer of Winship Cancer...
I Am Not Afraid of Cancer
At age 73, I’m no shrinking violet and I don’t run to the doctor at the first sign of a problem. I practice naturopathy and can usually ward off potential health issues by maintaining a healthy diet and lifestyle. When I began experiencing some mild discomfort in my rectum 2½ years ago, I was...
Computerized Cognitive Training Promising for Reducing Cognitive Late Effects in Childhood Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Heather M. Conklin, PhD, of St. Jude Children’s Research Hospital, and colleagues found that computerized cognitive training showed promise in reducing cognitive late effects in survivors of childhood cancer.1 Study Details In the study,...
Exploratory Analysis of ExteNET Trial Shows Consistency of Benefit With Neratinib
An exploratory analysis of the ExteNET study of neratinib in early HER2-positive breast cancer after treatment with trastuzumab (Herceptin) upheld the findings previously reported for the 2-year analysis, according to the study’s principal investigator Arlene Chan, MD, of the Breast Cancer...
Expert Point of View: George Sledge, MD
George Sledge, MD, Professor, and Chief, Division of Oncology, Stanford University Medical Center, told The ASCO Post that he found the data from the pooled analysis “very exciting.” “One of the big questions in triple-negative breast cancer is how to select which drugs work best for which...
Homologous Recombination Deficiency Score Correlated With Response to Platinum in Breast Cancer
The homologous recombination deficiency (HRD) score may be a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple-negative breast cancer, according to studies presented at the 2015 San Antonio Breast Cancer Symposium. “We found, in our adjusted analysis,...
Pancreas Cancer Liquid Biopsy: Proof-of-Principle Study
Pancreatic cancer tumors are ripe for analysis with a liquid biopsy, according to researchers at The University of Texas MD Anderson Cancer Center. In a proof-of-principle study published recently in Annals of Oncology,1 the investigators reported on research in which they conducted whole-genome,...
Uridine Triacetate Granules for Fluorouracil or Capecitabine Overdose or Early Severe Toxicity
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 11, 2015, uridine triacetate (Vistogard) was approved...
Expert Point of View: Angela DeMichele, MD, and Melinda L. Telli, MD
The formal discussant for the CALGB 40603 and GeparSixto studies at the San Antonio Breast Cancer Symposium was Angela DeMichele, MD, Professor of Medicine and Miller Chair in Breast Cancer Excellence at the Perelman School of Medicine, University of Pennyslvania. “The key questions raised by these ...
